Inhibitory effects of epigenetic modulators and differentiation inducers on human medulloblastoma cell lines

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Patties, Ina ^a   Kortmann, Rolf Dieter ^a   Glasow, Annegret ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

5 Aza 2' deoxycytidine; Abacavir; Medulloblastoma; Resveratrol; Retinoic acid; SAHA; Valproic acid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABACAVIR; GAMMA HISTONE H2AX; HISTONE H2AX; RESVERATROL; RETINOIC ACID; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG RESPONSE; EPIGENETICS; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; CELL PROLIFERATION; CEREBELLAR NEOPLASMS; DNA BREAKS, DOUBLE-STRANDED; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; HUMANS; MEDULLOBLASTOMA; NEOPLASM GRADING; TRETINOIN; TUMOR STEM CELL ASSAY; VALPROIC ACID;

EID: 84877636993     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-27     Document Type: Article

References (55)

1. Subtypes of medulloblastoma have distinct developmental origins. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Nature 2010 468 1095 1099 10.1038/nature09587 21150899
2. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R, Neuro Oncol 2008 10 1040 1060 10.1215/15228517-2008-059 18676356
3. The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells. Rossi A, Russo G, Puca A, La MR, Caputo M, Mattioli E, Lopez M, Giordano A, Pentimalli F, Int J Cancer 2009 125 235 243 10.1002/ijc.24331 19358275
4. Inhibition of STAT3 expression and signaling in resveratrol- differentiated medulloblastoma cells. Yu LJ, Wu ML, Li H, Chen XY, Wang Q, Sun Y, Kong QY, Liu J, Neoplasia 2008 10 736 744 18592012 (Pubitemid 351883890)
5. Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Wang Q, Li H, Wang XW, Wu DC, Chen XY, Liu J, Neurosci Lett 2003 351 83 86 10.1016/j.neulet.2003.07.002 14583387 (Pubitemid 37329594)
6. HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. Chai G, Li L, Zhou W, Wu L, Zhao Y, Wang D, Lu S, Yu Y, Wang H, McNutt MA, PLoS One 2008 3 2445 10.1371/journal.pone.0002445 18560576
7. CRABP-II methylation: a critical determinant of retinoic acid resistance of medulloblastoma cells. Fu YS, Wang Q, Ma JX, Yang XH, Wu ML, Zhang KL, Kong QY, Chen XY, Sun Y, Chen NN, Mol Oncol 2012 6 48 61 10.1016/j.molonc.2011.11.004 22153617
8. Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines. Patties I, Jahns J, Hildebrandt G, Kortmann RD, Glasow A, Strahlenther Onkol 2009 185 331 338 10.1007/s00066-009- 1956-1 19440673
9. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. Hagemann S, Heil O, Lyko F, Brueckner B, PLoS One 2011 6 17388 10.1371/journal.pone.0017388 21408221
10. Phase specificity of 5-azacytidine against mammalian cells in tissue culture. Li LH, Olin EJ, Fraser TJ, Bhuyan BK, Cancer Res 1970 30 2770 2775 5487064
11. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Santi DV, Norment A, Garrett CE, Proc Natl Acad Sci USA 1984 81 6993 6997 10.1073/pnas.81.22.6993 6209710 (Pubitemid 15216684)
12. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD, Mol Cell Biol 2008 28 752 771 10.1128/MCB.01799-07 17991895
13. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL, BMC Cancer 2008 8 128 10.1186/1471-2407-8-128 18454857 (Pubitemid 351715874)
14. Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Boivin AJ, Momparler LF, Hurtubise A, Momparler RL, Anticancer Drugs 2002 13 869 874 10.1097/00001813-200209000-00013 12394273
15. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC, Mol Cancer Ther 2005 4 1912 1922 10.1158/1535-7163.MCT-05-0184 16373706 (Pubitemid 43056974)
16. Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Shu Q, Antalffy B, Su JM, Adesina A, Ou CN, Pietsch T, Blaney SM, Lau CC, Li XN, Clin Cancer Res 2006 12 4687 4694 10.1158/1078-0432.CCR-05-2849 16899619 (Pubitemid 44297822)
17. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Ecke I, Petry F, Rosenberger A, Tauber S, Monkemeyer S, Hess I, Dullin C, Kimmina S, Pirngruber J, Johnsen SA, Cancer Res 2009 69 887 895 10.1158/0008-5472.CAN-08- 0946 19155313
18. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP, Nature 1999 401 188 193 10.1038/43710 10490031 (Pubitemid 29436325)
19. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Richon VM, Sandhoff TW, Rifkind RA, Marks PA, Proc Natl Acad Sci USA 2000 97 10014 10019 10.1073/pnas.180316197 10954755
20. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S, Int J Oncol 2007 30 1181 1188 17390020
21. Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Hacker S, Karl S, Mader I, Cristofanon S, Schweitzer T, Krauss J, Rutkowski S, Debatin KM, Fulda S, Oncogene 2011 30 2275 2281 10.1038/onc.2010.599 21562496
22. Interaction of deoxyguanosine nucleotide analogs with human telomerase. Tendian SW, Parker WB, Mol Pharmacol 2000 57 695 699 10727514 (Pubitemid 30183708)
23. A survey of telomerase activity in human cancer. Shay JW, Bacchetti S, Eur J Cancer 1997 33 787 791 10.1016/S0959-8049(97)00062-2 9282118 (Pubitemid 27239490)
24. Molecular analysis of PinX1 in medulloblastomas. Chang Q, Pang JC, Li J, Hu L, Kong X, Ng HK, Int J Cancer 2004 109 309 314 10.1002/ijc.11689 14750185 (Pubitemid 38240936)
25. Retinoic acid-induced neural differentiation of embryonal carcinoma cells. Jones-Villeneuve EM, Rudnicki MA, Harris JF, McBurney MW, Mol Cell Biol 1983 3 2271 2279 6656766 (Pubitemid 14224710)
26. Retinoic acid-induced differentiation of human neuroblastoma: a cell variant system showing two distinct responses. Sidell N, Sarafian T, Kelly M, Tsuchida T, Haussler M, Exp Cell Biol 1986 54 287 300 3026862 (Pubitemid 17219703)
27. Neuronal differentiation of cloned human teratoma cells in response to retinoic acid in vitro. Webb M, Graham C, Walsh F, J Neuroimmunol 1986 11 67 86 10.1016/0165-5728(86)90076-7 3511087 (Pubitemid 16148645)
28. All-trans-retinoic acid-induced apoptosis in human medulloblastoma: activation of caspase-3/poly(ADP-ribose) polymerase 1 pathway. Gumireddy K, Sutton LN, Phillips PC, Reddy CD, Clin Cancer Res 2003 9 4052 4059 14519626 (Pubitemid 37204020)
29. All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line. Chang Q, Chen Z, You J, McNutt MA, Zhang T, Han Z, Zhang X, Gong E, Gu J, J Neurooncol 2007 84 263 267 10.1007/s11060-007-9380-9 17453147
30. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Hallahan AR, Pritchard JI, Chandraratna RA, Ellenbogen RG, Geyer JR, Overland RP, Strand AD, Tapscott SJ, Olson JM, Nat Med 2003 9 1033 1038 10.1038/nm904 12872164 (Pubitemid 37021783)
31. Resveratrol in human cancer chemoprevention-choosing the 'right' dose. Scott E, Steward WP, Gescher AJ, Brown K, Mol Nutr Food Res 2012 56 7 13 10.1002/mnfr.201100400 22218912
32. The anticancer effects of resveratrol: modulation of transcription factors. Whitlock NC, Baek SJ, Nutr Cancer 2012 64 493 502 10.1080/01635581. 2012.667862 22482424
33. Old wine in a new bottle: the Warburg effect and anticancer mechanisms of resveratrol. Muqbil I, Beck FW, Bao B, Sarkar FH, Mohammad RM, Hadi SM, Azmi AS, Curr Pharm Des 2012 18 1645 1654 10.2174/138161212799958567 22288443
34. c-Myc downregulation: a critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of human medulloblastoma cells. Zhang P, Li H, Wu ML, Chen XY, Kong QY, Wang XW, Sun Y, Wen S, Liu J, J Neurooncol 2006 80 123 131 10.1007/s11060-006-9172-7 16724266 (Pubitemid 44614792)
35. The toxicity of poisons applied jointly1. Bliss CI, Ann Appl Biol 1939 26 585 615 10.1111/j.1744-7348.1939.tb06990.x
36. A three-dimensional model to analyze drug-drug interactions. Prichard MN, Shipman C Jr, Antiviral Res 1990 14 181 205 10.1016/0166-3542(90)90001-N 2088205 (Pubitemid 20377558)
37. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G, Leuk Res 2005 29 739 748 10.1016/j.leukres.2004.11.022 15927669 (Pubitemid 40779480)
38. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, Liu K, J Immunol 2012 188 4441 4449 10.4049/jimmunol.1103035 22461695
39. Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. Brodska B, Otevrelova P, Holoubek A, Mol Cell Biochem 2011 350 71 80 10.1007/s11010-010-0683-3 21153863
40. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC Jr, Cancer 2011 117 4424 4438 10.1002/cncr.26073 21491416
41. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults DW, Cancer Res 2005 65 919 924 15705891 (Pubitemid 40216452)
42. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Cancer Epidemiol Biomarkers Prev 2007 16 1246 1252 10.1158/1055-9965.EPI-07-0022 17548692 (Pubitemid 46984966)
43. p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing. Badiali M, Iolascon A, Loda M, Scheithauer BW, Basso G, Trentini GP, Giangaspero F, Diagn Mol Pathol 1993 2 23 28 8287222 (Pubitemid 23197494)
44. The mutation status of PAX3 and p53 genes in medulloblastoma. Wang W, Kumar P, Wang W, Whalley J, Schwarz M, Malone G, Haworth A, Kumar S, Anticancer Res 1998 18 849 853 9615731 (Pubitemid 28239606)
45. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Adesina AM, Nalbantoglu J, Cavenee WK, Cancer Res 1994 54 5649 5651 7923211
46. Infrequent p53 gene mutations in medulloblastomas. Saylors RL III, Sidransky D, Friedman HS, Bigner SH, Bigner DD, Vogelstein B, Brodeur GM, Cancer Res 1991 51 4721 4723 1873817
47. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, Bouffet E, Malkin D, Hawkins C, J Clin Oncol 2010 28 1345 1350 10.1200/JCO.2009.23.5952 20142599
48. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Huang C, Ma WY, Goranson A, Dong Z, Carcinogenesis 1999 20 237 242 10.1093/carcin/20.2.237 10069459 (Pubitemid 29057555)
49. Resveratrol induces p53-independent, X-linked inhibitor of apoptosis protein (XIAP)-mediated Bax protein oligomerization on mitochondria to initiate cytochrome c release and caspase activation. Gogada R, Prabhu V, Amadori M, Scott R, Hashmi S, Chandra D, J Biol Chem 2011 286 28749 28760 10.1074/jbc.M110.202440 21712378
50. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Radford IR, Int J Radiat Biol Relat Stud Phys Chem Med 1986 49 611 620 3485603 (Pubitemid 16105460)
51. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA, Agarwal R, Carcinogenesis 2005 26 1978 1987 10.1093/carcin/bgi165 15975956 (Pubitemid 41631273)
52. SIRT1 deacetylates APE1 and regulates cellular base excision repair. Yamamori T, DeRicco J, Naqvi A, Hoffman TA, Mattagajasingh I, Kasuno K, Jung SB, Kim CS, Irani K, Nucleic Acids Res 2010 38 832 845 10.1093/nar/gkp1039 19934257
53. A role for p53 in base excision repair. Zhou J, Ahn J, Wilson SH, Prives C, EMBO J 2001 20 914 923 10.1093/emboj/20.4.914 11179235 (Pubitemid 32167655)
54. Protective effects of resveratrol on cisplatin-dependent inner-ear damage in rats. Simsek G, Tokgoz SA, Vuralkan E, Caliskan M, Besalti O, Akin I, Eur Arch Otorhinolaryngol 2012 270 1789 1793 23001434
55. Chemoprotective action of resveratrol and genistein from apoptosis induced in human peripheral blood lymphocytes. Subbiah U, Raghunathan M, J Biomol Struct Dyn 2008 25 425 434 10.1080/07391102.2008.10507191 18092837